Emergent BioSolutions (EBS) Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Emergent BioSolutions in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" EBS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EBS, but not buy additional shares or sell existing shares.
View EBS analyst ratings or view top-rated stocks.

5 brokerages have issued 12 month price targets for Emergent BioSolutions' stock. Their EBS share price forecasts range from $9.00 to $55.00. On average, they predict the company's stock price to reach $28.00 in the next year. This suggests a possible upside of 242.3% from the stock's current price.
View analysts price targets for EBS or view top-rated stocks among Wall Street analysts.

Emergent BioSolutions' stock was trading at $11.81 at the start of the year. Since then, EBS shares have decreased by 30.7% and is now trading at $8.18.
View the best growth stocks for 2023 here.

Emergent BioSolutions saw a decrease in short interest in the month of April. As of April 30th, there was short interest totaling 6,650,000 shares, a decrease of 7.5% from the April 15th total of 7,190,000 shares. Based on an average trading volume of 1,810,000 shares, the days-to-cover ratio is presently 3.7 days. Currently, 15.1% of the company's shares are sold short.
View Emergent BioSolutions' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 7th 2023.
View our EBS earnings forecast.

Emergent BioSolutions Inc. (NYSE:EBS) released its quarterly earnings data on Tuesday, May, 9th. The biopharmaceutical company reported ($3.17) earnings per share for the quarter, missing analysts' consensus estimates of ($1.67) by $1.50. The biopharmaceutical company earned $165.10 million during the quarter, compared to analysts' expectations of $142.85 million. Emergent BioSolutions had a negative net margin of 41.20% and a negative trailing twelve-month return on equity of 20.18%. The firm's revenue was down 46.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.18 EPS.

ETFs with the largest weight of Emergent BioSolutions (NYSE:EBS) stock in their portfolio include Invesco S&P SmallCap 600 Pure Value ETF (RZV), ETFMG Treatments Testing and Advancements ETF (GERM), Cultivar ETF (CVAR), Invesco S&P SmallCap Health Care ETF (PSCH), First Trust Small Cap Value AlphaDEX Fund (FYT), SPDR S&P Biotech ETF (XBI), ALPS Medical Breakthroughs ETF (SBIO) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).

Emergent BioSolutions issued an update on its FY 2023 earnings guidance on Tuesday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.10 billion-$1.20 billion, compared to the consensus revenue estimate of $1.13 billion.

38 employees have rated Emergent BioSolutions Chief Executive Officer Bob Kramer on Glassdoor.com. Bob Kramer has an approval rating of 74% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent BioSolutions investors own include NVIDIA (NVDA), Salesforce (CRM), Novavax (NVAX), Advanced Micro Devices (AMD), Block (SQ), Netflix (NFLX), Gilead Sciences (GILD), PayPal (PYPL), Johnson & Johnson (JNJ) and AbbVie (ABBV).

Emergent BioSolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

Emergent BioSolutions' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (18.37%), State Street Corp (10.72%), Dimensional Fund Advisors LP (3.59%), Hotchkis & Wiley Capital Management LLC (1.87%), Geode Capital Management LLC (1.78%) and Charles Schwab Investment Management Inc. (1.63%). Insiders that own company stock include Fuad El-Hibri, George A Joulwan, Kathryn C Zoon, Louis W Sullivan, Richard S Lindahl, Robert Kramer, Ronald Richard, Sue Bailey and Zsolt Harsanyi.
View institutional ownership trends.

Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EBS stock can currently be purchased for approximately $8.18.

Emergent BioSolutions (NYSE:EBS) has a market capitalization of $412.68 million and generates $1.12 billion in revenue each year. The biopharmaceutical company earns $-223,800,000.00 in net income (profit) each year or ($8.06) on an earnings per share basis.

The company employs 2,500 workers across the globe.

Emergent BioSolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The official website for the company is www.emergentbiosolutions.com. The biopharmaceutical company can be reached via phone at (240) 631-3200, via email at burrowsr@ebsi.com, or via fax at 301-795-1899.